181 related articles for article (PubMed ID: 37377898)
1. Chemokine Analysis in Patients with Metastatic Uveal Melanoma Suggests a Role for CCL21 Signaling in Combined Epigenetic Therapy and Checkpoint Immunotherapy.
Sah VR; Jespersen H; Karlsson J; Nilsson LM; Bergqvist M; Johansson I; Carneiro A; Helgadottir H; Levin M; Ullenhag G; Ståhlberg A; Olofsson Bagge R; Nilsson JA; Ny L
Cancer Res Commun; 2023 May; 3(5):884-895. PubMed ID: 37377898
[TBL] [Abstract][Full Text] [Related]
2. The PEMDAC phase 2 study of pembrolizumab and entinostat in patients with metastatic uveal melanoma.
Ny L; Jespersen H; Karlsson J; Alsén S; Filges S; All-Eriksson C; Andersson B; Carneiro A; Helgadottir H; Levin M; Ljuslinder I; Olofsson Bagge R; Sah VR; Stierner U; Ståhlberg A; Ullenhag G; Nilsson LM; Nilsson JA
Nat Commun; 2021 Aug; 12(1):5155. PubMed ID: 34453044
[TBL] [Abstract][Full Text] [Related]
3. Concomitant use of pembrolizumab and entinostat in adult patients with metastatic uveal melanoma (PEMDAC study): protocol for a multicenter phase II open label study.
Jespersen H; Olofsson Bagge R; Ullenhag G; Carneiro A; Helgadottir H; Ljuslinder I; Levin M; All-Eriksson C; Andersson B; Stierner U; Nilsson LM; Nilsson JA; Ny L
BMC Cancer; 2019 May; 19(1):415. PubMed ID: 31046743
[TBL] [Abstract][Full Text] [Related]
4. Chemotrap-1: an engineered soluble receptor that blocks chemokine-induced migration of metastatic cancer cells in vivo.
Lanati S; Dunn DB; Roussigné M; Emmett MS; Carriere V; Jullien D; Budge J; Fryer J; Erard M; Cailler F; Girard JP; Bates DO
Cancer Res; 2010 Oct; 70(20):8138-48. PubMed ID: 20736366
[TBL] [Abstract][Full Text] [Related]
5. CCL21 chemokine regulates chemokine receptor CCR7 bearing malignant melanoma cells.
Takeuchi H; Fujimoto A; Tanaka M; Yamano T; Hsueh E; Hoon DS
Clin Cancer Res; 2004 Apr; 10(7):2351-8. PubMed ID: 15073111
[TBL] [Abstract][Full Text] [Related]
6. Tobacco exposure primes the secretion of CCL21 positively associated with tertiary lymphoid structure and response to immunotherapy.
Yin X; Wang H; Li R; Song X; Zhang T; Liang Y; Chen YZ; Yu X; Mao Q; Xia W; Chen B; Xu L; Dong G; Jiang F
J Immunother Cancer; 2023 Jun; 11(6):. PubMed ID: 37369391
[TBL] [Abstract][Full Text] [Related]
7. Immune profiling of uveal melanoma identifies a potential signature associated with response to immunotherapy.
Qin Y; Bollin K; de Macedo MP; Carapeto F; Kim KB; Roszik J; Wani KM; Reuben A; Reddy ST; Williams MD; Tetzlaff MT; Wang WL; Gombos DS; Esmaeli B; Lazar AJ; Hwu P; Patel SP
J Immunother Cancer; 2020 Nov; 8(2):. PubMed ID: 33203661
[TBL] [Abstract][Full Text] [Related]
8. Prognostic factors and outcomes in metastatic uveal melanoma treated with programmed cell death-1 or combined PD-1/cytotoxic T-lymphocyte antigen-4 inhibition.
Heppt MV; Heinzerling L; Kähler KC; Forschner A; Kirchberger MC; Loquai C; Meissner M; Meier F; Terheyden P; Schell B; Herbst R; Göppner D; Kiecker F; Rafei-Shamsabadi D; Haferkamp S; Huber MA; Utikal J; Ziemer M; Bumeder I; Pfeiffer C; Schäd SG; Schmid-Tannwald C; Tietze JK; Eigentler TK; Berking C
Eur J Cancer; 2017 Sep; 82():56-65. PubMed ID: 28648699
[TBL] [Abstract][Full Text] [Related]
9. Low-dose paclitaxel improves the therapeutic efficacy of recombinant adenovirus encoding CCL21 chemokine against murine cancer.
Chen P; Luo S; Wen YJ; Li YH; Li J; Wang YS; Du LC; Zhang P; Tang J; Yang DB; Hu HZ; Zhao X; Wei YQ
Cancer Sci; 2014 Nov; 105(11):1393-401. PubMed ID: 25230206
[TBL] [Abstract][Full Text] [Related]
10. A 12-chemokine gene signature is associated with the enhanced immunogram scores and is relevant for precision immunotherapy.
Li X; Wan Z; Liu X; Ou K; Yang L
Med Oncol; 2022 Jan; 39(4):43. PubMed ID: 35092511
[TBL] [Abstract][Full Text] [Related]
11. Cautious addition of targeted therapy to PD-1 inhibitors after initial progression of BRAF mutant metastatic melanoma on checkpoint inhibitor therapy.
Samlowski W; Adajar C
BMC Cancer; 2021 Nov; 21(1):1187. PubMed ID: 34743688
[TBL] [Abstract][Full Text] [Related]
12. A phase I/randomized phase II study of GM.CD40L vaccine in combination with CCL21 in patients with advanced lung adenocarcinoma.
Gray JE; Chiappori A; Williams CC; Tanvetyanon T; Haura EB; Creelan BC; Kim J; Boyle TA; Pinder-Schenck M; Khalil F; Altiok S; Devane R; Noyes D; Mediavilla-Varela M; Smilee R; Hopewell EL; Kelley L; Antonia SJ
Cancer Immunol Immunother; 2018 Dec; 67(12):1853-1862. PubMed ID: 30209589
[TBL] [Abstract][Full Text] [Related]
13. Low CCL-21 expression associates with unfavorable postoperative prognosis of patients with metastatic renal cell carcinoma.
Xiong Y; Liu L; Wang J; Xi W; Xia Y; Bai Q; Qu Y; Long Q; Xu J; Guo J
Oncotarget; 2017 Apr; 8(15):25650-25659. PubMed ID: 27783999
[TBL] [Abstract][Full Text] [Related]
14. Clinical outcomes in metastatic uveal melanoma treated with PD-1 and PD-L1 antibodies.
Algazi AP; Tsai KK; Shoushtari AN; Munhoz RR; Eroglu Z; Piulats JM; Ott PA; Johnson DB; Hwang J; Daud AI; Sosman JA; Carvajal RD; Chmielowski B; Postow MA; Weber JS; Sullivan RJ
Cancer; 2016 Nov; 122(21):3344-3353. PubMed ID: 27533448
[TBL] [Abstract][Full Text] [Related]
15. Delivery of CCL21 to metastatic disease improves the efficacy of adoptive T-cell therapy.
Thanarajasingam U; Sanz L; Diaz R; Qiao J; Sanchez-Perez L; Kottke T; Thompson J; Chester J; Vile RG
Cancer Res; 2007 Jan; 67(1):300-8. PubMed ID: 17210711
[TBL] [Abstract][Full Text] [Related]
16. Circulating immune profile can predict survival of metastatic uveal melanoma patients: results of an exploratory study.
Rossi E; Zizzari IG; Di Filippo A; Acampora A; Pagliara MM; Sammarco MG; Simmaco M; Lionetto L; Botticelli A; Bria E; Marchetti P; Blasi MA; Tortora G; Schinzari G; Nuti M
Hum Vaccin Immunother; 2022 May; 18(3):2034377. PubMed ID: 35258435
[TBL] [Abstract][Full Text] [Related]
17. Phase I Trial of Intratumoral Injection of
Lee JM; Lee MH; Garon E; Goldman JW; Salehi-Rad R; Baratelli FE; Schaue D; Wang G; Rosen F; Yanagawa J; Walser TC; Lin Y; Park SJ; Adams S; Marincola FM; Tumeh PC; Abtin F; Suh R; Reckamp KL; Lee G; Wallace WD; Lee S; Zeng G; Elashoff DA; Sharma S; Dubinett SM
Clin Cancer Res; 2017 Aug; 23(16):4556-4568. PubMed ID: 28468947
[No Abstract] [Full Text] [Related]
18. Clinical activity of ipilimumab for metastatic uveal melanoma: a retrospective review of the Dana-Farber Cancer Institute, Massachusetts General Hospital, Memorial Sloan-Kettering Cancer Center, and University Hospital of Lausanne experience.
Luke JJ; Callahan MK; Postow MA; Romano E; Ramaiya N; Bluth M; Giobbie-Hurder A; Lawrence DP; Ibrahim N; Ott PA; Flaherty KT; Sullivan RJ; Harding JJ; D'Angelo S; Dickson M; Schwartz GK; Chapman PB; Wolchok JD; Hodi FS; Carvajal RD
Cancer; 2013 Oct; 119(20):3687-95. PubMed ID: 23913718
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of lifileucel, a one-time autologous tumor-infiltrating lymphocyte (TIL) cell therapy, in patients with advanced melanoma after progression on immune checkpoint inhibitors and targeted therapies: pooled analysis of consecutive cohorts of the C-144-01 study.
Chesney J; Lewis KD; Kluger H; Hamid O; Whitman E; Thomas S; Wermke M; Cusnir M; Domingo-Musibay E; Phan GQ; Kirkwood JM; Hassel JC; Orloff M; Larkin J; Weber J; Furness AJS; Khushalani NI; Medina T; Egger ME; Graf Finckenstein F; Jagasia M; Hari P; Sulur G; Shi W; Wu X; Sarnaik A
J Immunother Cancer; 2022 Dec; 10(12):. PubMed ID: 36600653
[TBL] [Abstract][Full Text] [Related]
20. Immunotherapeutic effects of cytokine-induced killer cells combined with CCL21/IL15 armed oncolytic adenovirus in TERT-positive tumor cells.
Ye JF; Lin YQ; Yu XH; Liu MY; Li Y
Int Immunopharmacol; 2016 Sep; 38():460-7. PubMed ID: 27380620
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
